EMA Authorised: Arikayce liposomal (amikacin sulfate) — Insmed Netherlands B.V.

View source ↗

Summary

The EMA authorised Arikayce liposomal amikacin sulfate for use in respiratory tract infections, with orphan medicine designation; the marketing authorization ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-tuberculous Mycobacterial Lung Disease

Drugs mentioned

• Arikayce liposomal (amikacin sulfate)

Snippet

Status: Authorised. Therapeutic area: Respiratory Tract Infections. MAH: Insmed Netherlands B.V.. Decision date: 18/09/2025. Orphan medicine